Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph W Chow

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Jac-Antimicrobial Resistance|July 29, 2025
Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)George L Daikos, José Miguel Cisneros, Yehuda Carmeli, et al.
Pediatrics|March 4, 2009
A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patientsTheoklis E Zaoutis, Hasan S Jafri, Li-Min Huang, et al.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Jac-Antimicrobial Resistance|July 29, 2025
Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)George L Daikos, José Miguel Cisneros, Yehuda Carmeli, et al.
Pediatrics|March 4, 2009
A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patientsTheoklis E Zaoutis, Hasan S Jafri, Li-Min Huang, et al.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
Pageof 4